{"id":"doi:10.1002/acn3.70560","kind":"article","title":"A Two-Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p-Tau217 Gray Zone","authors":["Parankusham H","Vanderlip C","Birkenbihl C","Krishna E","Ugboaja C","Budson AE","Frank B"],"author_count":7,"year":2026,"published":"2026-10-19","venue":"Annals of clinical and translational neurology","cited_by":0,"doi":"10.1002/acn3.70560","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1002/acn3.70560","archive_url":"https://space-kitty.com/papers/doi:10.1002/acn3.70560","updated":null,"pmid":"42897700","pmcid":"PMC13680551","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC13680551/pdf","abstract":"Objective Plasma p-Tau217 leaves 30%-50% of patients in an indeterminate \"gray zone\" often requiring Aβ-PET. We developed GRAD (Gatekeeper-Reflex for Alzheimer's Disease), a two-stage Aβ-positivity prediction model to improve classification while reserving Aβ-PET for residual uncertainty. Methods GRAD was developed in 145 cognitively impaired ADNI participants and externally validated in 1644 cognitively unimpaired A4/LEARN participants. Stage 1 used p-Tau217 alone; probabilities between 0.25 and 0.75 were considered indeterminate. Stage 2 used L2-regularized logistic regression combining plasma-biomarkers, genetic and demographic features. Aβ-PET served as the reference standard (ADNI florbetapir SUVR > 1.11; A4 Centiloid ≥ 20). Results Full model AUC was 0.915 (95% CI, 0.859-0.961) internally and 0.879 (95% CI, 0.861-0.895) externally. In the external gray zone (n = 630), Stage 2 improved discrimination over p-Tau217 alone (AUC 0.793 vs. 0.719; p < 0.001), increased correct classification without PET from 41.4% to 56.2%, and reduced PET referral from 35.9% to 24.3%. In the p-Tau181 subset (n = 256), Stage 2 outperformed p-Tau181 (AUC 0.799 vs. 0.597; p < 0.001). Overall, 89.0% of ADNI and 90.7% of A4/LEARN participants were classified without PET; modeled testing costs were 44%-52% lower than p-Tau217 screening with PET confirmation of the gray zone. Interpretation Reflex multimarker testing improves indeterminate p-Tau217 classification while retaining Aβ-PET for residual uncertainty. GRAD may reduce PET use and testing costs in memory-clinic triage, prevention-trial enrichment, and disease-modifying therapy workup.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"A Two-Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p-Tau217 Gray Zone\" by Parankusham H, Vanderlip C, Birkenbihl C et al., https://doi.org/10.1002/acn3.70560, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}